focus -WSS

focus

author：explore 2025-09-29 09:29:57 - browse：8134

3D dollar signs come out of a prescription drug bottle — coverage from STAT — Adobe

WASHINGTON — Venture capitalists are still pouring money into drug research in spite of Medicare’s new power to negotiate drug prices, according to Congress’ nonpartisan budget experts.

The Inflation Reduction Act includes two measures that directly lower drug prices. Medicare price negotiation is the most controversial of the two. The law gives drugs 9 years on the market before negotiated prices take effect; biologics get 13 years. Drugs are selected for negotiation among the 50 top-selling drugs without generic or biosimilar competition. Medicare will negotiate prices for 10 drugs to start. Up to 60 drugs will be subject to negotiation over the next four years, and up to 20 more drugs every year afterward.

The law also requires drug companies to pay back Medicare when they raise prices on drugs faster than inflation.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： Independent physicians launch a new lobbying group

Wikipedia

WSS

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

People can get long Covid without testing positive for virus: Study

Independent physicians launch a new lobbying group

Readout Newsletter: Merck, J&J, and long Covid

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

AI generated plenty of interest at JPM but not a lot of trust

entertainment

focus

focus

Medical leaders decry Supreme Court decision on affirmative action

As obesity drug market grows, telehealth companies court payers

Affirmative action in medical school literally saved lives

Health officials lay out plans to cope with respiratory virus season

The high cost of giving birth even with insurance

As obesity drug market grows, telehealth companies court payers

Psychedelics group wrestles with new pharma identity

Dewpoint Therapeutics lays off staff after losing partnerships

New air purifier tech could be key to improving indoor air quality

Roche's accidental data boosts hopes for anti

entertainment

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Parkinson’s finding may lead to tests and, someday, treatments

Intellia plays down concerns on accidental germline transmission

CDC says it’s too soon to assess risk posed by Covid subvariant

Drugmakers bet big on mRNA for cancer. Why's Biden going in?

Republicans love RFK Jr. What's that tell us about health in 2024?

leisure time

hotspot

Wikipedia

focus